December 2015
·
159 Reads
This page lists the scientific contributions of an author, who either does not have a ResearchGate profile, or has not yet added these contributions to their profile.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
December 2015
·
159 Reads
December 2015
·
56 Reads
December 2015
·
257 Reads
April 2012
·
2,692 Reads
·
8 Citations
Pharmaceutical Technology
Controlling and monitoring impurities in APIs and finished drug products is a crucial issue in drug development and manufacturing. Part I of this article, published in the February 2012 issue of Pharmaceutical Technology, discussed the various types of and sources of impurities with specific case studies (1). Part II, published in the March 2012 issue, examined chiral, polymorphic, and genotoxic impurities (2). In Part III, the authors examine various degradation routes of APIs, impurities arising from API–excipient interaction during formulation, metabolite impurities, various analytical methodologies to measure impurity levels, and ways to control impurities in pharmaceuticals.
March 2012
·
40 Reads
·
5 Citations
Pharmaceutical Technology
March 2012
·
2,928 Reads
·
3 Citations
Pharmaceutical Technology
The public and the pharmaceutical industry are placing greater attention on impurities in drug as evidenced by the attention given to pharmaceutical impurities in books, journal articles, and national and international guidelines (1–10). The health implications of impurities can be significant because of their potential teratogenic, mutagenic, or carcinogenic effects. Controlling and monitoring impurities in APIs and finished drug products, therefore, is a crucial issue in drug development and manufacturing. Part I of this article, which appeared in the February 2012 issue of Pharmaeceutical Technology, discussed the various types and sources of impurities with specific case studies (11). This article, Part II, discusses chiral, polymorphic, and genotoxic impurities (12, 13). Part III, to be published in the April 2012 issue of Pharmaceutical Technology, will examine various degradation routes of APIs, impurities arising from API–excipient interaction during formulation, metabolite impurities, various analytical methodologies to measure impurity levels, and measures to control impurities.
February 2012
·
3,184 Reads
·
7 Citations
Pharmaceutical Technology
To ensure the quality of APIs and finished drug products, impurities must be monitored carefully during process development, optimization, and process changeover. The isolation, characterization, and control of impurities in pharmaceutical substances are being reviewed with greater attention based on national regulatory and international guidelines. In Part I of this article, the authors examine the different types and sources of impurities with specific examples.
January 2012
·
1,359 Reads
Pharmaceutical Technology
... Circular Dichroism detector could particularly determine the enantiomeric composition of drugs without prior enantioseparation. The effects of enantiomers of chiral drugs are elucidated in Table 1 given below [4][5][6]. ...
March 2012
Pharmaceutical Technology
... The pH reduction may be due to chemical degradation of the preparation or byproducts of microbial contamination (e.g., lactic acid which makes vinegar fermentation) that cause a change in the pH of liquid drug preparations [10]. Also, the presence of impurities in drug substances may lead to a change (reduction) in pH values [11]. Mean of three measurements, SD= Standard Deviation, n= number of measurements. ...
February 2012
Pharmaceutical Technology
... 10,11 Trace contaminants differ from chemical impurities directly connected to the synthesis of the API (e.g., products from side reactions) and can arise from residual catalysts or reagents used during synthesis or as an impurity leached from equipment during manufacturing. 12,13 During lead optimization, quality assessment is vital to verify that the biological effect seen in an assay is due to the compound itself 14 and not an impurity 15,16 and so that any undesired effects seen (e.g., selectivity, toxicology, safety) can be unambiguously attributed to the test article. Whereas it is usually straightforward to quantify impurities that are present at higher levels (1−5 mol %) using conventional techniques such as nuclear magnetic resonance (NMR), trace-level impurities (<1 mol %) such as metal residues arising from catalysts can be "silent" because they are present at levels below instrument limits of detection. ...
April 2012
Pharmaceutical Technology